• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病所致进行性执行功能障碍综合征:55例病例描述及与其他表型的比较

Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes.

作者信息

Townley Ryan A, Graff-Radford Jonathan, Mantyh William G, Botha Hugo, Polsinelli Angelina J, Przybelski Scott A, Machulda Mary M, Makhlouf Ahmed T, Senjem Matthew L, Murray Melissa E, Reichard Ross R, Savica Rodolfo, Boeve Bradley F, Drubach Daniel A, Josephs Keith A, Knopman David S, Lowe Val J, Jack Clifford R, Petersen Ronald C, Jones David T

机构信息

Department of Neurology Mayo Clinic, Rochester, MN 55902, USA.

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55902, USA.

出版信息

Brain Commun. 2020;2(1):fcaa068. doi: 10.1093/braincomms/fcaa068. Epub 2020 May 27.

DOI:10.1093/braincomms/fcaa068
PMID:32671341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7325839/
Abstract

We report a group of patients presenting with a progressive dementia syndrome characterized by predominant dysfunction in core executive functions, relatively young age of onset and positive biomarkers for Alzheimer's pathophysiology. Atypical frontal, dysexecutive/behavioural variants and early-onset variants of Alzheimer's disease have been previously reported, but no diagnostic criteria exist for a progressive dysexecutive syndrome. In this retrospective review, we report on 55 participants diagnosed with a clinically defined progressive dysexecutive syndrome with F-fluorodeoxyglucose-positron emission tomography and Alzheimer's disease biomarkers available. Sixty-two per cent of participants were female with a mean of 15.2 years of education. The mean age of reported symptom onset was 53.8 years while the mean age at diagnosis was 57.2 years. Participants and informants commonly referred to initial cognitive symptoms as 'memory problems' but upon further inquiry described problems with core executive functions of working memory, cognitive flexibility and cognitive inhibitory control. Multi-domain cognitive impairment was evident in neuropsychological testing with executive dysfunction most consistently affected. The frontal and parietal regions which overlap with working memory networks consistently demonstrated hypometabolism on positron emission tomography. Genetic testing for autosomal dominant genes was negative in all eight participants tested and at least one ε allele was present in 14/26 participants tested. EEG was abnormal in 14/17 cases with 13 described as diffuse slowing. Furthermore, CSF or neuroimaging biomarkers were consistent with Alzheimer's disease pathophysiology, although CSF p-tau was normal in 24% of cases. Fifteen of the executive predominate participants enrolled in research neuroimaging protocols and were compared to amnestic ( = 110), visual ( = 18) and language ( = 7) predominate clinical phenotypes of Alzheimer's disease. This revealed a consistent pattern of hypometabolism in parieto-frontal brain regions supporting executive functions with relative sparing of the medial temporal lobe (versus amnestic phenotype), occipital (versus visual phenotype) and left temporal (versus language phenotype). We propose that this progressive dysexecutive syndrome should be recognized as a distinct clinical phenotype disambiguated from behavioural presentations and not linked specifically to the frontal lobe or a particular anatomic substrate without further study. This clinical presentation can be due to Alzheimer's disease but is likely not specific for any single aetiology. Diagnostic criteria are proposed to facilitate additional research into this understudied clinical presentation.

摘要

我们报告了一组患者,他们表现出一种进行性痴呆综合征,其特征为核心执行功能存在主要功能障碍、发病年龄相对较轻且具有阿尔茨海默病病理生理学的阳性生物标志物。此前已报道过非典型额叶、执行功能障碍/行为变异型和早发型阿尔茨海默病,但尚无针对进行性执行功能障碍综合征的诊断标准。在这项回顾性研究中,我们报告了55名被诊断为临床定义的进行性执行功能障碍综合征的参与者,他们均有F - 氟脱氧葡萄糖 - 正电子发射断层扫描及阿尔茨海默病生物标志物数据。62%的参与者为女性,平均受教育年限为15.2年。报告的症状起始平均年龄为53.8岁,而诊断时的平均年龄为57.2岁。参与者及 informant 通常将最初的认知症状称为“记忆问题”,但进一步询问后发现存在工作记忆、认知灵活性和认知抑制控制等核心执行功能方面的问题。在神经心理学测试中多领域认知障碍明显,执行功能障碍受影响最为一致。与工作记忆网络重叠的额叶和顶叶区域在正电子发射断层扫描中持续显示代谢减低。所有8名接受检测的参与者常染色体显性基因的基因检测均为阴性,26名接受检测的参与者中有14名至少存在一个ε等位基因。17例中有14例脑电图异常,其中13例表现为弥漫性减慢。此外,脑脊液或神经影像学生物标志物与阿尔茨海默病病理生理学一致,尽管24%的病例脑脊液磷酸化tau蛋白正常。15名以执行功能为主的参与者纳入了研究神经影像学方案,并与遗忘型(n = 110)、视觉型(n = 18)和语言型(n = 7)为主的阿尔茨海默病临床表型进行比较。这揭示了顶叶 - 额叶脑区代谢减低的一致模式,这些脑区支持执行功能,而内侧颞叶(与遗忘型表型相比)、枕叶(与视觉型表型相比)和左侧颞叶(与语言型表型相比)相对保留。我们建议应将这种进行性执行功能障碍综合征视为一种与行为表现相区分的独特临床表型,在没有进一步研究的情况下,不应特别与额叶或特定解剖底物相关联。这种临床表现可能由阿尔茨海默病引起,但可能并非特定于任何单一病因。我们提出了诊断标准,以促进对这种研究不足的临床表现的进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f8/7425385/d979b6bca12e/fcaa068f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f8/7425385/d979b6bca12e/fcaa068f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46f8/7425385/d979b6bca12e/fcaa068f9.jpg

相似文献

1
Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes.阿尔茨海默病所致进行性执行功能障碍综合征:55例病例描述及与其他表型的比较
Brain Commun. 2020;2(1):fcaa068. doi: 10.1093/braincomms/fcaa068. Epub 2020 May 27.
2
The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.阿尔茨海默病的行为/执行功能障碍变异型:临床、神经影像学和病理特征
Brain. 2015 Sep;138(Pt 9):2732-49. doi: 10.1093/brain/awv191. Epub 2015 Jul 2.
3
The Behavioral/Dysexecutive Variant of Alzheimer's Disease: A Case Series with Clinical, Neuropsychological, and FDG-PET Characterization.阿尔茨海默病的行为/执行功能障碍变异型:一系列具有临床、神经心理学和 FDG-PET 特征的病例。
Dement Geriatr Cogn Disord. 2020;49(5):518-525. doi: 10.1159/000511210. Epub 2020 Nov 18.
4
Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases.揭示执行功能障碍和行为退行性疾病的独特宏观解剖结构。
Brain. 2024 Apr 4;147(4):1483-1496. doi: 10.1093/brain/awad356.
5
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.Tau正电子发射断层扫描(PET)模式反映了阿尔茨海默病的临床和神经解剖学变异性。
Brain. 2016 May;139(Pt 5):1551-67. doi: 10.1093/brain/aww027. Epub 2016 Mar 8.
6
Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.阿尔茨海默病导致进行性执行功能障碍综合征的表型亚型:一系列临床病例。
J Neurol. 2022 Aug;269(8):4110-4128. doi: 10.1007/s00415-022-11025-x. Epub 2022 Feb 25.
7
Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.在三种存在潜在阿尔茨海默病病理学特征的情况下,对氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)和匹兹堡化合物B正电子发射断层扫描(PiB-PET)进行并行独立成分分析。
Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.
8
Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.遗忘型患者的特征表现为代谢低下模式,提示路易体病理。
Brain. 2023 Nov 2;146(11):4520-4531. doi: 10.1093/brain/awad194.
9
Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease.在可能的阿尔茨海默病的临床变异型中,淀粉样蛋白沉积和低代谢的模式存在差异。
Brain. 2013 Mar;136(Pt 3):844-58. doi: 10.1093/brain/aws327. Epub 2013 Jan 28.
10
Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.认知和神经影像学特征以及阿尔茨海默病风险个体的脑β-淀粉样蛋白(INSIGHT-preAD):一项纵向观察性研究。
Lancet Neurol. 2018 Apr;17(4):335-346. doi: 10.1016/S1474-4422(18)30029-2. Epub 2018 Feb 27.

引用本文的文献

1
Frontal Variant Alzheimer's Disease or Primary Psychiatric Disorder? A Case Report.额颞叶型阿尔茨海默病还是原发性精神障碍?一例报告
Reports (MDPI). 2025 Feb 18;8(1):24. doi: 10.3390/reports8010024.
2
Combating Genetic Heterogeneity for Polygenic Prediction of Susceptibility to Brain β-Amyloid Deposition: Beyond .对抗基因异质性以进行脑β淀粉样蛋白沉积易感性的多基因预测:超越……
Neurol Genet. 2025 Jul 21;11(4):e200266. doi: 10.1212/NXG.0000000000200266. eCollection 2025 Aug.
3
Relationship between tau-PET and quantitative susceptibility mapping in atypical Alzheimer's disease.

本文引用的文献

1
Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum.认知谱内简易精神状态检查与蒙特利尔认知评估的比较。
Mayo Clin Proc. 2019 Aug;94(8):1516-1523. doi: 10.1016/j.mayocp.2019.01.043. Epub 2019 Jul 4.
2
The frontoparietal network: function, electrophysiology, and importance of individual precision mapping.额顶叶网络:功能、电生理学及个体精确映射的重要性
Dialogues Clin Neurosci. 2018 Jun;20(2):133-140. doi: 10.31887/DCNS.2018.20.2/smarek.
3
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
非典型阿尔茨海默病中tau正电子发射断层扫描与定量磁化率成像的关系
Front Aging Neurosci. 2025 Jul 3;17:1615718. doi: 10.3389/fnagi.2025.1615718. eCollection 2025.
4
An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders.一种基于氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)的机器学习框架,以支持阿尔茨海默病及相关疾病的神经学决策制定。
Neurology. 2025 Jul 22;105(2):e213831. doi: 10.1212/WNL.0000000000213831. Epub 2025 Jun 27.
5
Clinical phenotypes of Alzheimer's disease: investigating atrophy patterns and their pathological correlates.阿尔茨海默病的临床表型:研究萎缩模式及其病理相关性。
Alzheimers Res Ther. 2025 Apr 26;17(1):93. doi: 10.1186/s13195-025-01727-5.
6
Aβ and p-tau 181 as disease biomarkers in atypical Alzheimer's disease.β淀粉样蛋白和磷酸化tau蛋白181作为非典型阿尔茨海默病的疾病生物标志物。
J Alzheimers Dis. 2025 Jun;105(3):923-931. doi: 10.1177/13872877251333450. Epub 2025 Apr 23.
7
Longitudinal Evolution of Posterior Cortical Atrophy: Diagnostic Delays, Overlapping Phenotypes, and Clinical Outcomes.后皮质萎缩的纵向演变:诊断延迟、重叠表型及临床结局
Neurology. 2025 May 13;104(9):e213559. doi: 10.1212/WNL.0000000000213559. Epub 2025 Apr 8.
8
Donanemab: Appropriate use recommendations.多那单抗:合理使用建议。
J Prev Alzheimers Dis. 2025 May;12(5):100150. doi: 10.1016/j.tjpad.2025.100150. Epub 2025 Mar 27.
9
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics.用于早期阿尔茨海默病的莱卡奈单抗:法国记忆诊所联合会的合理使用建议
J Prev Alzheimers Dis. 2025 Apr;12(4):100094. doi: 10.1016/j.tjpad.2025.100094. Epub 2025 Feb 25.
10
Impact of the polygenic risk scores for attention-deficit/hyperactivity disorder in Alzheimer's disease.注意力缺陷多动障碍的多基因风险评分对阿尔茨海默病的影响。
Alzheimers Dement. 2025 Feb;21(2):e70003. doi: 10.1002/alz.70003.
遗传性阿尔茨海默病的纵向认知和生物标志物变化。
Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.
4
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架:迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
5
Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum.tau、淀粉样蛋白和阿尔茨海默病谱中的级联网络故障。
Cortex. 2017 Dec;97:143-159. doi: 10.1016/j.cortex.2017.09.018. Epub 2017 Oct 3.
6
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.tau蛋白病变和神经退行性变导致阿尔茨海默病的认知障碍。
Brain. 2017 Dec 1;140(12):3286-3300. doi: 10.1093/brain/awx243.
7
Apathy, but not depression, is associated with executive dysfunction in cerebral small vessel disease.在脑小血管病中,冷漠而非抑郁与执行功能障碍有关。
PLoS One. 2017 May 11;12(5):e0176943. doi: 10.1371/journal.pone.0176943. eCollection 2017.
8
Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.在四个队列中,明确识别出可能的阿尔茨海默病的认知亚型。
Alzheimers Dement. 2017 Nov;13(11):1226-1236. doi: 10.1016/j.jalz.2017.03.002. Epub 2017 Apr 17.
9
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.推荐用于痴呆诊断评估的 CSF AD 生物标志物。
Alzheimers Dement. 2017 Mar;13(3):274-284. doi: 10.1016/j.jalz.2016.09.008. Epub 2016 Oct 27.
10
Consensus classification of posterior cortical atrophy.后皮质萎缩的共识分类
Alzheimers Dement. 2017 Aug;13(8):870-884. doi: 10.1016/j.jalz.2017.01.014. Epub 2017 Mar 2.